Clinical Trial Update: Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating a multi-agent regimen (pixantrone, etoposide, bendamustine +/- rituximab) in relapsed aggressive non-Hodgkin lymphomas of B- or T-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Etoposide (Etoposide)
• Pixantrone (pixantrone)
• Rituximab (rituximab)

Snippet

Sponsor: University of Aarhus | Conditions: Malignant Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN